N@N

Antisense: Antisense Therapeutics to Present at Rodman & Renshaw 11th Annual Healthcare Conference

_{//health-fitness.news-articles.net/content/2009/ .. n-renshaw-11th-annual-healthcare-conference.html}
^{Published in Health and Fitness on Monday, August 31st 2009 at 7:48 GMT by Market Wire}  

MELBOURNE, AUSTRALIA--(Marketwire - August 31, 2009) - Antisense Therapeutics Limited (PINKSHEETS: [ ATHJY ]) (ASX: [ ANP ]) today announced that the Company is scheduled to present at the Rodman & Renshaw 11th Annual Global Healthcare Conference, on September 9th-11th in New York City.

Mark Diamond, Antisense Therapeutics' Chief Executive Officer, will give a presentation on Wednesday, September 9th at 10:25 a.m. EST in the Hubbard Salon at the NY Palace Hotel. Mr. Diamond will provide an overview of the Company's drug development pipeline with focus on the Company's lead compound, ATL/TV1102 for Multiple Sclerosis (MS), which has been licensed to Teva Pharmaceutical Industries. The presentation will be followed by a question and answer session and a live webcast may be accessed at the Company's website, [ www.antisense.com.au ].

A replay of the presentation will be archived for 90 days after the conference, at the same location. For more information about the Rodman & Renshaw 11th Annual Healthcare Conference, please visit Rodman & Renshaw's website at [ www.rodmanandrenshaw.com ].

Antisense management will be available for meetings in New York on September 9th and 10th.

In April 2009, at the American Academy of Neurology (AAN) 61st Annual Meeting in Seattle, Washington, Antisense's presentation of the clinical study results from its Phase II ATL/TV1102 MS study was selected as being in the top 5 percent of abstracts judged to be the most critical new research out of more than 2000 studies presented over the entire scientific program of the meeting.

In the study, it was demonstrated that ATL/TV1102, a second-generation antisense drug designed to specifically inhibit the production of VLA-4 (a clinically validated target in MS), significantly reduced the number of new active lesions in patients with relapsing remitting MS taking ATL/TV1102 for 8 weeks, compared to placebo.

About Antisense Therapeutics Limited

Antisense Therapeutics Limited (ASX: [ ANP ]) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise antisense pharmaceuticals for large unmet markets. ANP has two drugs in development and two drugs in pre-clinical research. ATL1102 (injection) is in the advanced stages of a Phase IIa trial as a potential treatment of multiple sclerosis. ATL1103 is a second-generation antisense drug designed to lower blood IGF-I levels and is entering preclinical development as a potential treatment for acromegaly and vision disorders. ATL1102 (inhaled) is at the pre-clinical research stage as a potential treatment for asthma. ATL1101 is a second-generation antisense drug at the pre-clinical research stage being investigated as a potential treatment for prostate cancer. ATL1102 has been licensed to Teva Pharmaceutical Industries Ltd.

Website: [ www.antisense.com.au ]